G
Gerhard Fierlbeck
Researcher at University of Tübingen
Publications - 107
Citations - 4226
Gerhard Fierlbeck is an academic researcher from University of Tübingen. The author has contributed to research in topics: Melanoma & Systemic scleroderma. The author has an hindex of 34, co-authored 107 publications receiving 3836 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna,Christopher P. Denton,Angelika Jahreis,Jacob M van Laar,Tracy M. Frech,Marina E Anderson,Murray Baron,Lorinda Chung,Gerhard Fierlbeck,Santhanam Lakshminarayanan,Yannick Allanore,Janet E. Pope,Gabriela Riemekasten,Virginia D. Steen,Ulf Müller-Ladner,Robert Lafyatis,Giuseppina Stifano,Helen Spotswood,Haiyin Chen-Harris,Sebastian Dziadek,Alyssa Morimoto,Thierry Sornasse,Jeffrey Siegel,Daniel E. Furst +23 more
TL;DR: Tocilizumab was not associated with a significant reduction in skin thickening and should be investigated in a phase 3 trial before definitive conclusions can be made about its risks and benefits.
Journal ArticleDOI
Arterial embolization caused by injection of hyaluronic acid (Restylane).
Journal ArticleDOI
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement.
Nicolas Hunzelmann,Ekkehard Genth,T. Krieg,Walter Lehmacher,Inga Melchers,Michael Meurer,Pia Moinzadeh,Ulf Müller-Ladner,Christiane Pfeiffer,Gabriela Riemekasten,Eckhard Schulze-Lohoff,C. Sunderkoetter,Milena Weber,Margitta Worm,Pascal Klaus,A. Rubbert,K. Steinbrink,B. Grundt,R. Hein,Karin Scharffetter-Kochanek,R. Hinrichs,Kyle M. Walker,R.-M. Szeimies,Sigrid Karrer,Antje Müller,Cornelia S. Seitz,Enno Schmidt,Percy Lehmann,Ivan Foeldvari,Frank Reichenberger,Wolfgang L. Gross,Annegret Kuhn,M. Haust,Kristian Reich,Markus Böhm,P. Saar,Gerhard Fierlbeck,Ina Kötter,H.-M. Lorenz,Norbert Blank,K. Gräfenstein,Aaron Juche,Elisabeth Aberer,G. Bali,Christoph Fiehn,Rudolf Stadler,V. Bartels +46 more
TL;DR: In this nationwide register, a descriptive classification of patients with disease manifestations characteristic of SSc in five groups allows to include a broader spectrum of Patients with features of S sc to improve the detection and follow-up of patients presenting with different disease manifestations.
Journal ArticleDOI
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Dinesh Khanna,Christopher P. Denton,Celia J. F. Lin,Jacob M van Laar,Tracy M. Frech,Marina E Anderson,Murray Baron,Lorinda Chung,Gerhard Fierlbeck,Santhanam Lakshminarayanan,Yannick Allanore,Janet E. Pope,Gabriela Riemekasten,Virginia D. Steen,Ulf Müller-Ladner,Helen Spotswood,Laura Burke,Jeffrey Siegel,Angelika Jahreis,Daniel E. Furst +19 more
TL;DR: Skin score improvement and FVC stabilisation in the double-blind period were observed in placebo-treated patients who transitioned to tocilizumab and were maintained in the open-label period and safety data indicated increased serious infections in patients with SSc but no new safety signals with tocilIZumab.
Journal ArticleDOI
Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations.
TL;DR: It is concluded that interferon gamma is an important lymphokine in the development of psoriasis.